- Home
- APLM vs ATIF Comparison
APLM vs ATIF Comparison
Compare APLM & ATIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- ATIF
- Stock Information
- Founded
- APLM 2016
- ATIF 2015
- Country
- APLM United States
- ATIF United States
- Employees
- APLM N/A
- ATIF N/A
- Industry
- APLM Blank Checks
- ATIF Professional Services
- Sector
- APLM Finance
- ATIF Consumer Discretionary
- Exchange
- APLM Nasdaq
- ATIF Nasdaq
- Market Cap
- APLM 15.6M
- ATIF 12.6M
- IPO Year
- APLM N/A
- ATIF 2019
- Fundamental
- Price
- APLM $0.14
- ATIF $0.86
- Analyst Decision
- APLM Strong Buy
- ATIF
- Analyst Count
- APLM 2
- ATIF 0
- Target Price
- APLM $4.25
- ATIF N/A
- AVG Volume (30 Days)
- APLM 883.4K
- ATIF 7.1K
- Earning Date
- APLM 08-14-2024
- ATIF 11-11-2024
- Dividend Yield
- APLM N/A
- ATIF N/A
- EPS Growth
- APLM N/A
- ATIF N/A
- EPS
- APLM N/A
- ATIF N/A
- Revenue
- APLM $2,101,000.00
- ATIF $500,000.00
- Revenue This Year
- APLM N/A
- ATIF N/A
- Revenue Next Year
- APLM N/A
- ATIF N/A
- P/E Ratio
- APLM N/A
- ATIF N/A
- Revenue Growth
- APLM 70.54
- ATIF N/A
- 52 Week Low
- APLM $0.11
- ATIF $0.58
- 52 Week High
- APLM $2.90
- ATIF $1.45
- Technical
- Relative Strength Index (RSI)
- APLM 46.70
- ATIF 44.76
- Support Level
- APLM $0.13
- ATIF $0.73
- Resistance Level
- APLM $0.17
- ATIF $1.12
- Average True Range (ATR)
- APLM 0.01
- ATIF 0.17
- MACD
- APLM 0.00
- ATIF -0.03
- Stochastic Oscillator
- APLM 29.31
- ATIF 22.58
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About ATIF ATIF Holdings Limited
ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.